Key result
Amlodipine/valsartan combination therapy reduced mean sitting diastolic blood pressure compared to amlodipine monotherapy.
Why the study?
Does amlodipine/valsartan combination therapy reduce blood pressure in hypertensive patients not adequately controlled on amlodipine monotherapy?
RCT (n=944)
double-blind
randomised
Yes
Does amlodipine/valsartan combination therapy reduce blood pressure in hypertensive patients not adequately controlled on amlodipine monotherapy?
Adding valsartan to amlodipine significantly improves blood pressure control and reduces peripheral edema compared to continuing amlodipine monotherapy in patients with uncontrolled hypertension.
Answers are grounded in this paper and cite their sources.
Supports adding valsartan to amlodipine in uncontrolled hypertension; confirms additive BP reduction in this RCT population.
UNLABELLED: ABSTRACT (ARB), in essential hypertensive patients not adequately controlled by amlodipine monotherapy. METHODS: This was a multi-centre, randomised, double-blind, active-controlled study in patients with essential hypertension. After a washout period followed by a single-blind amlodipine 10 mg run-in period, patients with mean sitting diastolic blood pressure (msDBP) > or =90 mmHg and <110 mmHg were randomised to receive amlodipine/valsartan (10/160 mg o.d.) or amlodipine (10 mg o.d.) for 8 weeks. TRIAL REGISTRATION NUMBER: NCT00171002. MAIN OUTCOME MEASURES: The primary efficacy variable was change from baseline in msDBP at study endpoint. Secondary efficacy variables were change from baseline in mean sitting systolic blood pressure (msSBP), responder rate (msDBP <90 mmHg or > or =10 mmHg reduction from baseline) and DBP control rate (msDBP <90 mmHg). RESULTS: Of the 1283 patients enrolled in single-blind period, 944 were randomised to receive amlodipine/valsartan 10/160 mg (n = 473) and amlodipine 10 mg (n = 471). Statistically significant greater reductions (p < 0.0001) from baseline in msSBP/msDBP were observed with combination therapy (12.9/11.4 mmHg) compared to monotherapy (10.0/9.3 mmHg). Responder rate was significantly greater (p = 0.0011) with combination therapy (79.0%) compared to monotherapy (70.1%). The percentage of patients with controlled DBP was also significantly (p < 0.0001) higher with combination therapy (77.8%) compared to monotherapy (66.5%). Incidence of peripheral oedema was slightly higher with amlodipine monotherapy (9.4%) compared to combination therapy (7.6%). CONCLUSION: The combination of amlodipine/valsartan in this 8-week double-blind study provided additional BP control and was well tolerated in patients inadequately controlled with amlodipine monotherapy. Results should be interpreted with the knowledge that study entry criteria may limit application to a wider population.
No takes yet. Share an insight, caveat, or question.
Schunkert et al. (2009) conducted an RCT in essential hypertension (n=944). amlodipine/valsartan vs. amlodipine 10 mg o.d. was evaluated on change from baseline in msDBP at study endpoint (p=< 0.0001). Amlodipine/valsartan combination therapy reduced mean sitting diastolic blood pressure compared to amlodipine monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: